Marking an important day for those with atopic dermatitis, shares of two biopharmas surged on clinical data suggesting new biologics are on their way to help address 40% of patients with uncontrolled ...
The scale of the $8.5 billion deal signed between Innovent Biologics Inc. and Eli Lilly and Co. is eye-catching, but the ...
Hepatocellular carcinoma (HCC) is the most common form of primary liver cancer, representing approximately 75-85% of all cases. Often considered preventable, primary liver cancer ranks as the sixth ...
Myopia is a refractive disorder caused by excessive axial elongation, leading to blurred distance vision. Its development involves genetic, environmental and molecular factors, including retinal ...
Clinch Biosciences LLC has divulged myosin-2 (MYH2) inhibitors reported to be useful for the treatment of stroke, hypertension, acute kidney injury, gastrointestinal motility disorders and myocardial ...
Scientists from the Korea Research Institute of Chemical Technology and Yonsei University have identified N4-(indolin-7-yl)-N2-(2-alkoxypyridin-3-yl)pyrimidine-2,4-diamine derivatives acting as EGFR ...
Toll-like receptors (TLRs) are important regulators of immune responses upon recognition of pathogens or endogenous molecules released from damaged tissues. Among them, the endosomal TLRs TLR7 and ...
Iambic Therapeutics Inc.’s multiyear technology and discovery pact with Takeda Pharmaceutical Co. Ltd. could help the San Diego-based firm advance its own pipeline in a big way.
TMEM97 regulates microglial activation and neuronal stress pathways linked to neuropathic pain and neuroinflammation in multiple sclerosis (MS). Pharmacological targeting of TMEM97 has shown ...
Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in disease activity, thus there is a need for ...
Jiangsu Hansoh Pharmaceutical Group Co. Ltd. and Shanghai Hansoh Biomedical Co. Ltd. have discovered heterocyclic carbonyl derivatives acting as muscarinic M4 receptor agonists potentially useful for ...
Delonix Bioworks Ltd. has obtained IND clearance from China’s National Medical Products Administration (NMPA) for its group B meningococcal (MenB) vaccine candidate, DX-104. This follows the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results